Oncomatryx Biopharma S. L. is a pharmaceutical biotechnology company that develops personalized treatments against invasive cancer as well as tests for its early detection. Established by Laureano Simón, PhD, Oncomatryx thus engages twofold in the fight against invasive kinds of cancer, such as pancreatic cancer or invasive breast cancer, all of which have high mortality rates.
Oncomatryx's research focuses on peritumoral stroma, which has been found to take part in promoting cancer invasiveness and curtailing treatment efficacy.[1]
- ^ Chiang, Anne C.; Massagué, Joan (2008). "Molecular Basis of Metastasis". New England Journal of Medicine. 359 (26): 2814–2823. doi:10.1056/NEJMra0805239. PMC 4189180. PMID 19109576.